Myriad Genetics, Inc.
0K3W.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$397.69M
Close$
$-1.89
145% downside
Current Fair Value
145% downsideOvervalued by 145% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $397.69 Million |
|---|---|
| Enterprise Value | $492.99 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.95 |
| Beta | 1.64 |
| Outstanding Shares | 94,800,000 |
Return
| Return on Equity | -37.05% |
|---|---|
| Return on Assets | -17.62% |
| Return on Invested Capital | -18.85% |
Valuation & Multiples
| P/E Ratio | -3.61 |
|---|---|
| PEG | 4.15 |
| Price to Sales | 0.52 |
| Price to Book Ratio | 1.4 |
| Enterprise Value to Revenue | 0.61 |
| Enterprise Value to EBIT | -5.15 |
| Enterprise Value to Net Income | -5 |
| Total Debt to Enterprise | 0.43 |
| Debt to Equity | 0.69 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$206.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.20
Average shareholder expectationRevenue Estimate
$191.48 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Myriad Genetics, Inc.
2,600 employees
CEO: R. Bryan Riggsbee Myriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that: determine the risk of developing disease, accura...